Bill Skach, MD, executive vice president and chief scientific officer at the Cystic Fibrosis Foundation, talks about potential approaches for treating people with CF who have rare and nonsense mutations. These strategies include theratyping, small-molecule screening, and the use of transfer ribonucleic acid (RNA).
For more: [ Ссылка ]
